Journal Mobile Options
Table of Contents
Vol. 30, No. 5, 2012
Issue release date: October 2012
Dig Dis 2012;30:445–452

Promotion of Hepatocellular Carcinoma by Hepatitis C Virus

Bühler S. · Bartenschlager R.
Department of Infectious Diseases, Molecular Virology, Heidelberg University, Heidelberg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Persistent infection with the hepatitis C virus (HCV) is a major global health problem. Around 2–3% of the world’s population are chronically infected, and infected individuals are at high risk of developing steatosis, fibrosis, and liver cirrhosis. The latter is a major predisposing factor for the development of hepatocellular carcinoma (HCC). It is generally accepted that an inflammatory response triggered by persistent HCV infection leads to increased cell proliferation and fibrogenesis that in turn promotes cirrhosis and ultimately HCC development. This indirect mechanism of tumor induction would explain the long incubation period from primary HCV infection to HCC and the requirement for additional cofactors such as toxins or drugs (most notably alcohol), metabolic liver diseases, steatosis, nonalcoholic liver disease, or diabetes. With the advent of adequate cell culture systems for HCV it is, however, becoming increasingly clear that the virus also contributes directly to HCC formation. Examples are the continuous induction of stress response or the massive accumulation of intracellular lipids. Moreover, viral proteins can bind to and sequester cell cycle control factors such as the retinoblastoma protein or the tumor suppressor DDX3. Thus, HCV-associated liver cancer is most likely promoted by the combined action of long-term chronic inflammation and targeted perturbations of cellular key pathways involved in metabolic homeostasis as well as cell cycle control.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529–538.
  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
  3. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485–1491.
  4. Bartenschlager R, Sparacio S: Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res 2007;127:195–207.
  5. Lindenbach BD, Meuleman P, Ploss A, Vanwolleghem T, Syder AJ, McKeating JA, Lanford RE, Feinstone SM, Major ME, Leroux-Roels G, Rice CM: Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006;103:3805–3809.
  6. Levrero M: Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006;25:3834–3847.
  7. Tan A, Yeh SH, Liu CJ, Cheung C, Chen PJ: Viral hepatocarcinogenesis: from infection to cancer. Liver Int 2008;28:175–188.
  8. Rice CM: New insights into HCV replication: potential antiviral targets. Top Antivir Med 2011;19:117–120.
  9. Alvisi G, Madan V, Bartenschlager R: Hepatitis C virus and host cell lipids: an intimate connection. RNA Biol 2011;8:258–269.
  10. Poenisch M, Bartenschlager R: New insights into structure and replication of the hepatitis C virus and clinical implications. Semin Liver Dis 2010;30:333–347.
  11. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF: Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011;54:566–576.
  12. Bartenschlager R, Penin F, Lohmann V, Andre P: Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011;19:95–103.
  13. Sainz B, Jr., Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL: Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 2012;18:281–285.
  14. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoel M, Raffelsberger W, Poch O, Mc Keating JA, Brino L, Baumert TF: EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011;17:589–595.
  15. Lohmann V, Körner F, Koch JO, Herian U, Theilmann L, Bartenschlager R: Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999;285:110–113.
  16. McGivern DR, Lemon SM: Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011;30:1969–1983.
  17. Yamashita T, Honda M, Kaneko S: Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. J Gastroenterol Hepatol 2011;26:960–964.
  18. Seth D, Haber PS, Syn WK, Diehl AM, Day CP: Pathogenesis of alcohol-induced liver disease: classical concepts and recent advances. J Gastroenterol Hepatol 2011;26:1089–1105.
  19. Hwang SJ, Lee SD: Hepatic steatosis and hepatitis C: still unhappy bedfellows? J Gastroenterol Hepatol 2011;26(suppl 1):96–101.

    External Resources

  20. Owsianka AM, Patel AH: Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Virology 1999;257:330–340.
  21. McGivern DR, Villanueva RA, Chinnaswamy S, Kao CC, Lemon SM: Impaired replication of hepatitis C virus containing mutations in a conserved NS5B retinoblastoma protein-binding motif. J Virol 2009;83:7422–7433.
  22. Appel N, Schaller T, Penin F, Bartenschlager R: From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 2006;281:9833–9836.
  23. Bartosch B, Thimme R, Blum HE, Zoulim F: Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009;51:810–820.
  24. Fung J, Lai CL, Yuen MF: Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect 2009;15:964–970.
  25. Banerjee A, Ray RB, Ray R: Oncogenic potential of hepatitis C virus proteins. Viruses 2010;2:2108–2133.
  26. Beckham CJ, Parker R: P bodies, stress granules, and viral life cycles. Cell Host Microbe 2008;3:206–212.
  27. Colgan SM, Hashimi AA, Austin RC: Endoplasmic reticulum stress and lipid dysregulation. Expert Rev Mol Med 2011;13:e4.

    External Resources

  28. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D, Bienz K: Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. J Virol 2002;76:5974–5984.
  29. Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, Moradpour D: Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol 2003;77:5487–5492.
  30. Thiele C, Spandl J: Cell biology of lipid droplets. Curr Opin Cell Biol 2008;20:378–385.
  31. Goodman JM: The gregarious lipid droplet. J Biol Chem 2008;283:28005–28009.
  32. Martin S, Parton RG: Lipid droplets: a unified view of a dynamic organelle. Nat Rev Mol Cell Biol 2006;7:373–378.
  33. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, Bartenschlager R, Wakita T, Hijikata M, Shimotohno K: The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007;9:1089–1097.
  34. Boulant S, Targett-Adams P, McLauchlan J: Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol 2007;88:2204–2213.
  35. Shavinskaya A, Boulant S, Penin F, Mc Lauchlan J, Bartenschlager R: The lipid droplet binding domain of hepatitis C virus core protein is a major determinant for efficient virus assembly. J Biol Chem 2007;282:37158–37169.
  36. Moradpour D, Wakita T, Tokushige K, Carlson RI, Krawczynski K, Wands JR: Characterization of three novel monoclonal antibodies against hepatitis C virus core protein. J Med Virol 1996;48:234–241.
  37. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, Schaff Z, Chapman MJ, Miyamura T, Brechot C: Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997;94:1200–1205.
  38. Domitrovich AM, Felmlee DJ, Siddiqui A: Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem 2005;280:39802–39808.
  39. Boulant S, Douglas MW, Moody L, Budkowska A, Targett-Adams P, McLauchlan J: Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner. Traffic 2008;9:1268–1282.
  40. Angus AG, Dalrymple D, Boulant S, McGivern DR, Clayton RF, Scott MJ, Adair R, Graham S, Owsianka AM, Targett-Adams P, Li K, Wakita T, McLauchlan J, Lemon SM, Patel AH: Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol 2010;91:122–132.
  41. Herker E, Harris C, Hernandez C, Carpentier A, Kaehlcke K, Rosenberg AR, Farese RV Jr, Ott M: Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. Nat Med 2010;16:1295–1298.
  42. Harris C, Herker E, Farese RV Jr, Ott M: Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core- induced steatosis. J Biol Chem 2011;286:42615–42625.
  43. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM: Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927–933.
  44. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G: Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005;41:847–856.
  45. Bissig KD, Wieland SF, Tran P, Isogawa M, Le TT, Chisari FV, Verma IM: Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 2010;120:924–930.
  46. Washburn ML, Bility MT, Zhang L, Kovalev GI, Buntzman A, Frelinger JA, Barry W, Ploss A, Rice CM, Su L: A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease. Gastroenterology 2011;140:1334–1344.
  47. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A: A genetically humanized mouse model for hepatitis C virus infection. Nature 2011;474:208–211.
  48. Ruggieri A, Dazert E, Metz P, Hofmann S, Bergeest JP, Mazur J, Bankhead P, Hiet MS, Kallis S, Alvisi G, Samuel CE, Lohmann V, Kaderali L, Rohr K, Frese M, Stoecklin G, Bartenschlager R: Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection. Cell Host Microbe 2012;12:71–85.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50